Welcome to our dedicated page for Weed news (Ticker: BUDZ), a resource for investors and traders seeking the latest updates and insights on Weed stock.
undefined (BUDZ) is a global cannabis bioresearch innovator advancing therapeutic applications through clinical trials and rare strain development. This page provides essential updates on corporate milestones, regulatory compliance, and market strategies shaping the cannabis industry.
Access real-time announcements about clinical research progress, international expansion efforts, and consumer product launches. Users will find verified information on earnings reports, strategic partnerships, and quality assurance protocols that meet rigorous scientific standards.
Content spans regulatory filings, research publications, executive leadership updates, and patent developments. All materials are curated to support informed analysis of BUDZ's unique position at the intersection of biotechnology and cannabis commercialization.
Bookmark this resource for consolidated access to official updates from undefined (BUDZ), ensuring you remain informed about developments in cannabinoid research and global market strategies.
WEED Inc. (OTCQB: BUDZ) has released its 2024 highlights and 2025 plans. The company plans to expand into consumer packaged goods using rare Landrace cannabis strains. Key 2024 developments include: attendance at the Pharmaceutical Guild of Australia conference, deregistration of Cannabis Institute of Australia and WEED Hong Kong for cost reduction, and securing trademark registrations for 'Panama Red' and 'WEED' in USA and Canada. The company maintains five HEMP licenses in Arizona and is exploring THC grow licensing. WEED Inc. reports having no long-term debt, has never taken convertible notes, and has approximately 125 million shares outstanding with ~31 million shares in float through 2024.
WEED, Inc. (OTCQB: BUDZ) announced the acquisition of Hempirical Genetics, LLC for 2 million shares valued at $.25 per share and $250,000 in cash over four years. This strategic move, described as a 'game changer', enhances WEED's cannabis genetics programs with over 30 new CBD and CBG strains, ultimately aimed at product development and clinical trials. Jeffery Miller, the previous owner, will lead development at HEMP BioSciences. The company aims to innovate in medical cannabis and build a pipeline of effective products while addressing legal and market uncertainties.
WEED, Inc. (OTCQB:BUDZ) announced that WEED Australia Ltd. will attend the United in Compassion Australian Medicinal Cannabis Symposium from May 20-22, 2022, in Queensland. The event aims to enhance understanding of cannabis applications in medicine. Key representatives include CEO Glenn E. Martin and Managing Director Patrick Brodnik. Discussions will focus on potential partnerships and the evolving legal framework for medicinal cannabis in Australia, as more patients seek access. The company aims to lead cannabis research and product development in the Asia-Pacific region.
WEED, Inc. (OTCQB:BUDZ) announced that its subsidiary, WEED Australia Ltd., has completed its financial statement requirements under ASIC rules, paving the way for a formal public offering anticipated in 2022 or 2023. The company is seeking strategic partnerships to bolster development, with a focus on cannabis-derived compounds for medical applications. CEO Glenn E. Martin will attend the 'United in Compassion' conference in May 2022 to explore collaborative opportunities. Despite positive developments, investors are cautioned about the significant legal risks associated with cannabis operations in the U.S.
WEED, Inc. (OTCQB:BUDZ) announces its strategic focus on expanding its trademark portfolio in the cannabis industry, aiming for enhanced brand recognition and shareholder value. The company holds a registered WEED® trademark and is pursuing additional registrations for PANAMA RED™ and ACAPULCO GOLD™ across various products and services. Through these efforts, WEED, Inc. plans to solidify its position as a leader in the cannabis sector while actively engaging in healthcare innovations for both humans and pets.
WEED, Inc. (OTCQB:BUDZ) announced plans to develop the Sugar Hill Golf Course in Westfield, NY into a luxury cannabis-friendly resort. Having recently completed a purchase of the property for ~$250,000, which was appraised at $1.9 million, they aim to establish a cannabis research division and luxury condos. Future ambitions include edibles and beverage research. The company intends to form a New York division to expand R&D programs and has budgeted $40 million for various initiatives, though no funds have been raised yet for the resort project.
